The imidazopyridine zolpidem is a short-acting hypnotic chemically distinct
from benzodiazepines (BZs). According to its peculiar neuropharmacologic a
ctivity (selectivity for the omega 1-BZ receptors), zolpidem is expected to
be a pure hypnotic, without the other effects of BZs. In particular, it ha
s been stressed that zolpidem is well tolerated in adults and in the elderl
y, and that tolerance, abuse, dependence, rebound insomnia, and other withd
rawal effects do not develop in relation to zolpidem administration. Howeve
r, despite these assumptions, zolpidem abuse, dependence, and withdrawal ef
fects have been recently discussed and reviewed herein. In addition, the ca
se of a 43-year-old woman who had an epileptic attack after abrupt interrup
tion of an abused, high dose of zolpidem (600 mg/d), is reported and discus
sed. At the clinical level, it is stressed that the subjective effects of z
olpidem are comparable to those of other BZs, and that abuse, dependence, a
nd withdrawal seizures cannot be avoided simply shifting the regimen of a B
Z abuser to zolpidem. At the pharmacologic level, it is important to note t
hat zolpidem's clinical effects cannot be explained on the basis of the old
distinction between omega 1 and 2 receptors because this distinction is no
longer valid; the new classification of GABA(A) receptor subtypes is repor
ted and zolpidem activity at this level is discussed herein.